Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 3.01B 3.42B 2.8B 2.57B 4.83B 328B 4.89B 33.27B 13B 162B 12.84B 12.56B 560B P/E 2026 *
21x
P/E 2027 * 17.4x
Enterprise Value 2.99B 3.4B 2.78B 2.56B 4.8B 326B 4.86B 33.09B 12.93B 161B 12.77B 12.5B 557B EV / Sales 2026 *
3.88x
EV / Sales 2027 * 3.28x
Free-Float
31.63%
Yield 2026 *
1.64%
Yield 2027 * 1.99%
3 years 52
Extreme 52
90.61
5 years 0.03
Extreme 0.03
90.61
10 years 0.03
Extreme 0.03
90.61
Manager TitleAgeSince
Chief Executive Officer - 27/07/2007
Director of Finance/CFO - 01/01/2001
Chief Operating Officer - -
Director TitleAgeSince
Chairman - 17/07/2021
Director/Board Member - 27/07/2007
Director/Board Member - 27/07/2007
Change 5-day change 1-year change 3-year change Capi.($)
-27.31%-.--% - - 3.42B
+0.10%+4.25%+47.96%+162.79% 1,067B
+1.72%+7.57%+61.03%+54.11% 635B
-0.28%+2.12%+37.25%+73.83% 458B
+1.41%+8.56%+38.18%+32.17% 347B
+1.28%+4.40%+37.69%+41.62% 295B
+1.72%+4.10%+19.44%+20.45% 262B
+1.84%-0.46%-27.63%-38.65% 216B
+0.09%+3.20%+24.74%+59.22% 203B
+1.51%-1.42%+16.19%+71.64% 161B
Average -1.68%+1.33%+28.32%+53.02% 404.83B
Weighted average by Cap. +0.91%+1.95%+37.90%+78.44%

Financials

2026 *2027 *
Net sales 772M 878M 718M 660M 1.24B 84.18B 1.26B 8.54B 3.33B 41.57B 3.3B 3.22B 144B 891M 1.01B 829M 762M 1.43B 97.17B 1.45B 9.86B 3.85B 47.98B 3.8B 3.72B 166B
Net income 129M 146M 120M 110M 206M 14.02B 209M 1.42B 555M 6.92B 549M 537M 23.93B 174M 198M 162M 149M 279M 18.97B 283M 1.92B 751M 9.37B 743M 727M 32.37B
Net Debt -16.21M -18.44M -15.09M -13.86M -26.03M -1.77B -26.37M -179M -70.07M -873M -69.23M -67.74M -3.02B -81.51M -92.72M -75.87M -69.68M -131M -8.89B -133M -902M -352M -4.39B -348M -341M -15.17B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
2,470
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
58.80EUR
Average target price
74.36EUR
Spread / Average Target
+26.46%

Quarterly revenue - Rate of surprise